Vaxxinity, Inc. in brief
Vaxxinity, Inc. is a listed company in the Healthcare sector, based in the USA. Its last known market value was $95 M (January 2024); there is no current figure. In the year to Dec 2021 it had sales of $0 M and a net loss of $137 M. Its shares trade under the symbol VAXX (Nasdaq).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
Vaxxinity, Inc. timeline
- 2021
- 🔔· approximateInitial public offering on Nasdaq
Events of Vaxxinity, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,877 (Jan 2022) · #3,698 (Dec 2022) · #3,111 (Jul 2023) · #3,730 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -228333.3%
- Operating margin
- —
- Return on equity
- -107.0%
- Liabilities / assets
- 22.9%
Annual results
- Revenue
- $0 M
- Operating income
- —
- Net income
- $-137 M
Dec-2021 ending year
Balance sheet
- Total assets
- $166 M
- Total liabilities
- $38 M
- Total equity
- $128 M
Dec-2021 ending year
Markets and events: Vaxxinity, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 95 shares at $0.02
- : 100 shares at $0.02
- : 2,040 shares
- : 19,158 shares
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Lobbying by Vaxxinity, Inc.#
$170 K spent on lobbying the US Congress and federal agencies in 2022, most often on health issues, aerospace and defense.
- Health Issues4 reports
- Aerospace3 reports
- Defense3 reports
- Manufacturing3 reports
- Medical/Disease Research/Clinical Labs3 reports
- Veterans3 reports
Lobbying firms hired in 2022
BUCHANAN INGERSOLL & ROONEY PC $170 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $170 K | — | 4 |
H-1B hiring at Vaxxinity, Inc.#
1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $167 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Regulatory Affairs CMC Senior ManagerRegulatory Affairs Managers | 1 | $167 K |
Where: Edison, NJ 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2024 | 1 | 1 | $167 K | 1 |
| FY2023 | 1 | 1 | $167 K | 1 |
How Vaxxinity, Inc. compares in Healthcare
- Revenue$0 M · higher than 6% of 1,808
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Vaxxinity, Inc.🇺🇸 | $95 M | — | — | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- UnitedHealth Group Incorporated$367.7 B
- Merck & Co., Inc.$359.8 B
How current the figures are
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- Dec-2021 ending year
- Balance sheet:
- Dec-2021 ending year
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Vaxxinity, Inc.? Verify and update this profile — free
Show Vaxxinity, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.